Nanjing Powerstat Medical Technology
Nanjing Powerstat Medical Technology is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Sponsor Shanghai Henlius Biotech Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Sponsor Shanghai Henlius Biotech Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Nanjing Powerstat Medical Technology?
The 2026-10-09 snapshot links Nanjing Powerstat Medical Technology to 2 distinct CTIS trials. Recorded services include IDMC, Statistical analysis. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Nanjing Powerstat Medical Technology?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Nanjing Powerstat Medical Technology conducted?
The linked trials record locations in 13 countries, including Germany, Spain, Greece, Poland, Austria. These are trial locations, not confirmed office locations or countries where Nanjing Powerstat Medical Technology delivered services.
What can this page tell me about Nanjing Powerstat Medical Technology's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Nanjing Powerstat Medical Technology. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Nanjing Powerstat Medical Technology Co. Ltd.